Novartis AG (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 145   

Articles published

NVS 94.10 +0.19 (0.20%)
price chart
GSK Shareholders In Favor Of Novartis (NVS) Deal
GlaxoSmithKline plc (ADR) (NYSE:GSK) announced that its shareholders voted in ´┐Żoverwhelming majority´┐Ż in favor of the company's multi-billion swapping deal with Novartis AG (ADR) (NYSE:NVS) in the annual shareholder meeting held on December 18.
Related articles »  
FDA Okays Novartis AG's (NVS) Signifor LAR To Treat Acromegaly
Novartis AG (ADR) (NYSE:NVS) announced Tuesday that its drug Signifor LAR has been approved by the US Food and Drug Administration (FDA) to treat acromegaly in patients on whom prior treatments have not worked or for whom surgery is not an option.
Related articles »  
Novartis AG ADR (NVS): New Analyst Report from Zacks Equity Research ...
Novartis reported third-quarter 2014 earnings per share of $1.33, up 48% from the year-ago period. Core earnings per share came in at $1.37, up 10% from the year-ago period and beat the Zacks Consensus Estimate of $1.29.
Related articles »  
Novartis (NVS) Fails To Sidestep Patent Infringement
Novartis AG (ADR) (NYSE:NVS) has failed to invalidate Amgen Inc.'s (NASDAQ:AMGN) patents for the autoimmune drug Enbrel, as the US patent court decided to dismiss the suit filed by the former's generic division, Sandoz Inc. The company sought a ruling ...
Related articles »  
Here's Why Novartis AG (NVS) Stock Could Fall Today
Novartis AG (ADR) (NYSE:NVS) announced early Monday morning that its drug Gilenya failed to meet its primary endpoint in a Phase III study, called INFORMS, designed to measure the efficacy of the drug in treating primary-progressive multiple sclerosis ...
Related articles »  
Novartis (NVS) Beats Johnson & Johnson (JNJ) In Clinical Trial
Novartis AG's (ADR) (NYSE:NVS) plaque psoriasis treatment Cosentyx continued to produce impressive results in its clinical trial.
Related articles »  
Novartis AG (ADR) Boosts its Cancer Immunotherapy Presence
Despite outstanding performance over the past year from biotech and pharma, you wouldn't be alone if you think they have more room to grow.
Novartis (NVS) to acquire start-up CoStim Pharmaceuticals in immunotherapy ...  Stockhouse
Related articles »  
Investor Watch: Novartis AG (ADR) (NYSE:NVS), Whiting Petroleum Corp (NYSE ...
Novartis AG (ADR) (NYSE:NVS) was upgraded to a equal weight rating by analysts at Morgan Stanley. Analysts at Morgan Stanley believe that the company provides prime value to investors going forward and the growth trajectory for the company looks intact ...
Novartis AG Rating Increased to Equal Weight at Morgan Stanley (NVS)  Mideast Time
Related articles »  
Novartis' (NVS) Signifor Wins EU Approval For Rare Hormonal Disorder
Novartis AG (ADR) (NYSE:NVS) announced before US markets opened for trading Monday that the European Commission has approved its drug Signifor for the treatment of a rare hormonal disorder that is believed to affect about 1-2 in every 10,000 ...
Related articles »  
Novartis Posts Strong Third-Quarter Results; Cost-Cutting Efforts Pay Off
Novartis AG (ADR) (NVS) posted upbeat financial and operational results for the third quarter of its fiscal year (3QFY14) today before markets opened.
Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View - Analyst Blog  Nasdaq
Related articles »